BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.90
-0.10 (-0.34%)
Apr 29, 2026, 1:30 PM CST

BioGend Therapeutics Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
3,6064,7754,1814,7082,2472,757
Upgrade
Market Cap Growth
-8.01%14.21%-11.18%109.50%-18.50%-22.86%
Upgrade
Enterprise Value
3,1114,2693,5583,9901,7202,063
Upgrade
Last Close Price
29.0038.2833.5538.1321.7326.32
Upgrade
PS Ratio
16.2221.4824.9442.8371.46297.47
Upgrade
PB Ratio
4.766.304.944.923.072.92
Upgrade
P/TBV Ratio
5.537.336.096.094.734.53
Upgrade
EV/Sales Ratio
13.9919.2021.2236.3054.70222.54
Upgrade
Debt / Equity Ratio
0.010.010.010.010.020.01
Upgrade
Net Debt / Equity Ratio
-0.67-0.67-0.72-0.74-0.65-0.73
Upgrade
Net Debt / EBITDA Ratio
7.947.948.155.682.804.97
Upgrade
Net Debt / FCF Ratio
7.807.806.124.322.564.98
Upgrade
Asset Turnover
0.260.260.170.120.030.01
Upgrade
Inventory Turnover
3.413.412.291.891.240.64
Upgrade
Quick Ratio
16.8416.8421.0616.9016.7328.58
Upgrade
Current Ratio
17.6017.6021.6017.3217.0129.24
Upgrade
Return on Equity (ROE)
-11.88%-11.88%-13.30%-19.07%-24.54%-17.51%
Upgrade
Return on Assets (ROA)
-7.99%-7.99%-7.78%-11.79%-14.85%-11.74%
Upgrade
Return on Capital Employed (ROCE)
-14.20%-14.20%-13.90%-17.60%-27.70%-16.50%
Upgrade
Earnings Yield
-2.35%-1.77%-2.79%-3.32%-8.21%-5.02%
Upgrade
FCF Yield
-1.82%-1.37%-2.38%-3.50%-8.32%-4.99%
Upgrade
Buyback Yield / Dilution
---2.32%-16.69%-1.77%-15.90%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.